Rena Kaminsky

Cooley advised Senti Biosciences, a biotechnology company, on its sale of certain assets – including its manufacturing facility and chemistry, manufacturing, and controls capabilities – to Celadon Partners.

We represented Neurocrine Biosciences in its strategic collaboration and licensing agreement with Sosei Heptares to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment of schizophrenia, dementia and other neuropsychiatric disorders.

Under the terms of the agreement, Neurocrine Biosciences gains development and commercialization rights to a broad portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei Heptares in development for the treatment of major neurological disorders. Sosei Heptares received a total of $100 million in upfront cash and is eligible to receive up to approximately $1.5 billion related to the successful progression of licensed candidates through to regulatory approval. Sosei Heptares is also eligible to receive up to $1.1 billion upon achieving certain global sales milestones of any products developed under the partnership and is eligible to receive tiered royalties ranging from high single digit to mid-teen percentage on future net sales.

Lawyers Kay Chandler and Rena Kaminsky led the Cooley team advising Neurocrine.

Cooley advised Neurocrine Biosciences on its strategic partnership agreement with Takeda to develop and commercialize potential therapies in Takeda’s early- to mid-stage pipeline for psychiatric disorders. The partnership will enhance Neurocrine’s growing pipeline of treatments and strengthen the company’s position as a leading neuroscience-focused biopharmaceutical company.

Neurocrine will develop and commercialize all pipeline compounds included in the collaboration. Under the terms of the agreement, Neurocrine will pay Takeda $120 million in upfront cash and up to $495 million in development milestones, $1.4 billion in commercial milestones and double-digit royalties on net sales.

Cooley advised Zai Lab Limited, a China and U.S.-based innovative commercial stage biopharmaceutical company focused on developing medicines for cancer, infectious and autoimmune diseases to patients worldwide, on its global product commercialization collaboration with Regeneron Pharmaceuticals, Inc. This collaboration is focused on the development and commercialization of REGN1979, a bispecific antibody designed to treat lymphoma, in mainland China, Hong Kong, Taiwan, and Macau.

Fate Therapeutics in its global collaboration and option agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Under the multi-year collaboration agreement, Janssen will contribute proprietary antigen binding domains for up to four tumor-associated antigen targets. The Company will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor (CAR) NK and CAR T-cell product candidates.

Under the terms of the agreement, Janssen will receive $50 million in cash and $50 million from the purchase by Johnson & Johnson Innovation  JJDC, Inc. of newly issued shares of the Company’s common stock at a price per share of $31.00. Janssen is also eligible to receive payments of up to  $1.8 billion upon the achievement of development and regulatory milestones and up to $1.2 billion upon the achievement of commercial milestones, plus double-digit royalties on worldwide commercial sales of products targeting the antigens.